GlassScriptPhysician profile
Jonathan L Fellus
NPI 1053309195
$3,409.04
in general payments reported to CMS, 2019-2025
22 companies · $934 in 2025
The $934 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $28.44 · 2021: $257 · 2022: $921 · 2023: $81.42 · 2024: $883 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253 · Consulting Fee: $600 · Education: $44.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.24 |
| Consulting Fee | $600.00 |
| Education | $44.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $550.23 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $519.44 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $400.00 | 2024-2025 | Spravato |
| Janssen Pharmaceuticals, INC | $353.75 | 2022-2024 | Spravato |
| Axsome Therapeutics, INC. | $345.06 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Avadel Cns Pharmaceuticals, LLC | $313.31 | 2024-2025 | Lumryz |
| Biohaven Pharmaceutical Holding Company LTD. | $228.63 | 2022 | |
| Eisai INC. | $144.01 | 2024-2025 | |
| Neurelis, INC. | $115.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.80 | 2024-2025 | Trintellix |
| Acorda Therapeutics, INC | $75.65 | 2023-2024 | Inbrija, Ampyra |
| Lilly USA, LLC | $58.65 | 2024 | Amyvid |
| Avanir Pharmaceuticals, INC. | $56.87 | 2019-2020 | |
| Pfizer INC. | $33.96 | 2024 | |
| Biogen, INC. | $18.82 | 2025 | Leqembi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.20 | 2025 | |
| Amgen INC. | $17.13 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.59 | 2024 | Rytary |
| Argenx US, INC. | $15.39 | 2024 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $14.82 | 2024 | Xeomin |
| Bausch Health US, LLC | $14.75 | 2025 | Aplenzin |
| Biohaven Pharmaceuticals, INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fellus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.